Welcome to our dedicated page for Treace Medical Concepts SEC filings (Ticker: TMCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the FDA updates buried inside Treace Medical Concepts’ foot-and-ankle filings can feel like performing surgery without a scalpel. Each 10-K dissects patented Lapiplasty revenue, clinical study progress and competitive risks, while an 8-K may quietly announce a new regulatory milestone. That technical depth makes Treace Medical Concepts SEC filings complex, yet missing a single note could change your view of this high-growth medical-device innovator.
Stock Titan solves that problem. Our AI engine translates dense language into clear insights, so Treace Medical Concepts SEC filings explained simply becomes reality. Receive instant access to every document type—Treace Medical Concepts quarterly earnings report 10-Q filing, Treace Medical Concepts annual report 10-K simplified, and Treace Medical Concepts 8-K material events explained—the moment EDGAR posts them. Interactive dashboards surface segment revenue from the Lapiplasty system, flag device-approval disclosures and highlight risk-factor changes. Need trading intel? We stream Treace Medical Concepts Form 4 insider transactions real-time, making it easy to track Treace Medical Concepts executive stock transactions Form 4 before the market reacts.
Whether you are monitoring surgeon adoption rates, evaluating clinical-trial spending, or comparing proxy-statement pay packages (Treace Medical Concepts proxy statement executive compensation), Stock Titan’s AI-powered summaries, red-flag alerts and historical search tools put the right details within seconds. Use our platform to perform Treace Medical Concepts earnings report filing analysis, map insider buying patterns, and answer stakeholder questions like understanding Treace Medical Concepts SEC documents with AI. Every filing, every footnote—delivered faster than you can say “three-plane correction.”
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 6,260,000 shares of Treace Medical Concepts, Inc., representing 9.91% of the outstanding common stock based on 63,173,126 shares outstanding as of July 31, 2025. The reported position is held directly by Armistice Capital Master Fund Ltd. with Armistice Capital acting as investment manager and Steven Boyd as managing member. The Reporting Persons disclaim sole voting or dispositive power; all voting and dispositive power is reported as shared (6,260,000 shares). The Master Fund is identified as the direct holder and retains rights to dividends or sale proceeds.
Scot Michael Elder, Chief Legal & Compliance Officer and corporate secretary of Treace Medical Concepts (TMCI), reported a Form 4 disclosing an equity transaction dated 08/09/2025. The filing lists a transaction coded "F" involving 10,515 shares at a reported price of $0. After the reported transaction, Mr. Elder beneficially owns 566,149 shares, held directly.
The filing states the beneficial ownership total includes 480,103 restricted stock units and indicates no derivative securities were reported. This disclosure describes the insider's reported change in non-derivative equity holdings and the composition of the reported stake.
Mark Hair, Chief Financial Officer of Treace Medical Concepts (TMCI), reported a change in beneficial ownership of common stock on 08/09/2025. The Form 4 records a disposition of 22,212 shares with a transaction code labeled "F" and a reported transaction price of $0. After the reported transaction the filing shows Mr. Hair beneficially owns 518,964 shares directly; that total expressly includes 421,228 restricted stock units. The filing discloses the magnitude of the ownership change but does not provide explanation for the transaction code or the zero price.
Sean F. Scanlan, identified as Chief Innovation Officer of Treace Medical Concepts, Inc. (TMCI), reported a common stock transaction dated 08/09/2025 on a Form 4. The filing records a transaction coded F and shows the reporting line items 9,814 with a marker D and a post-transaction beneficial ownership total of 373,807 shares held directly.
The form includes an explanatory footnote that the beneficial ownership figure includes 284,798 restricted stock units. The filing was executed by an attorney-in-fact on behalf of Mr. Scanlan as indicated on the form.
Aaron Berutti, SVP, Sales at Treace Medical Concepts (TMCI), reported a change in beneficial ownership that results in 205,092 shares held beneficially. The filing shows a transaction dated 08/09/2025 listing 4,907 common shares with a recorded price of $0.
The reported total ownership explicitly includes 181,955 restricted stock units, per the form explanation. The disclosure is a Form 4 insider report reflecting an officer-level change in equity holdings; the filing does not provide additional context about the nature of the $0 price or whether the change arose from vesting, issuance, conversion, or another mechanism.
FAQ
What is the current stock price of Treace Medical Concepts (TMCI)?
What is the market cap of Treace Medical Concepts (TMCI)?
